We’re not only at the front lines of therapeutic advancement, we’re also continuously making headlines in healthcare, business, and research markets.


BeyondSpring Files 2021 Annual Report on Form 20-F

NEW YORK, April 14, 2022 – BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical...

read more

BeyondSpring Announces Organizational Streamlining

Resources to be Focused on Highest Value Business Activities   35% Reduction in Workforce in the U.S. Implemented to Preserve Long-Term Sustainability NEW YORK, January 11, 2022 – BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global...

read more